Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blinatumomab in Moderate to Severe Primary Sjögren's Syndrome
NCT07852234Phase 2Not yet recruiting
- Sponsor
- Beijing Tongren Hospital
- Start
- Sep 2026
- Primary completion
- Oct 2027
- Countries
- 1
01
Overview
A Phase 2 trial of blinatumomab in primary Sjögren's syndrome, sponsored by Beijing Tongren Hospital. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
blinatumomab
03
Conditions
primary Sjögren's syndrome
Beyond the preview
Go deeper on NCT07852234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07852234.